Registration is now closed,
as this program has already taken place.
Monday, 23 April 2018
Welcome Refreshments (wine, soft drinks, and hors d'oeuvres) & Registration
16:00 – 16:30
CME Symposium / Q&A Session
16:30 – 18:00
IFEMA - Feria de Madrid
Hall K
Avda. Del Partnon 5
28042 Madrid, Spain
PROGRAM AGENDA
16:00 – 16:30 |
|
Welcome Refreshments (wine, soft drinks, and hors d'oeuvres) & Registration |
16:30 – 16:35 |
|
Welcome and Introductions |
|
|
Mario Fernández-Ruiz, MD, PhD |
16:35 – 16:50 |
|
CMV in Transplant: Unmet Needs in Detection, Prevention, Prophylaxis, and Management |
|
|
Mario Fernández-Ruiz, MD, PhD |
16:50 – 17:10 |
|
Update on Current Management of CMV in Transplant Patients |
|
|
Atul Humar, MD, MSc, FRCP(C)
|
17:10 – 17:30 |
|
Emerging Therapies for CMV in Transplant Patients
|
|
|
Roy F. Chemaly, MD, MPH, FACP, FIDSA |
17:30 – 18:00 |
|
Clinical Cases, Panel Discussion, and Audience Q&A
|
|
|
All Faculty |
FACULTY
Mario Fernández-Ruiz, MD, PhD (Chair)
Unit of Infectious Diseases
University Hospital "12 de Octubre"
Madrid, Spain
Atul Humar, MD, MSc, FRCP(C)
Director, Transplant Program
University Health Network
Toronto, ON (Canada)
Roy F. Chemaly, MD, MPH, FACP, FIDSA
Professor of Medicine
Director, Infection Control Section
Director, Clinical Virology Research
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, TX (USA)
TARGET AUDIENCE
This activity has been designed to meet the educational needs of clinicians who manage cytomegalovirus (CMV) infection in transplant patients.
LEARNING OBJECTIVES
After participating in this educational activity, participants should be better able to:
- Implement prophylactic and preventive anti-CMV therapy in at-risk transplant patients as recommended by the current evidence base
- Promptly diagnose transplant patients with CMV infection and disease, using new and emerging assays and tools
- Apply clinical trial data for new and emerging treatment options to manage transplant patients infected with CMV, including those with resistant or refractory disease
- Identify and address adverse events of agents used for prophylaxis and treatment of CMV infection and disease
ACCREDITATION STATEMENT
The New Advances in Transplant Medicine: Cytomegalovirus Diagnosis, Prevention, and Treatment, Madrid, Spain, 23/04/2018-23/04/2018 has been accredited by the European Accreditation
Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s).
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of
AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at
www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
DISCLOSURE DECLARATION
It is the policy of RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
FEE INFORMATION
There is no fee for this educational activity.
PROVIDER STATEMENT
Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.